DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,616 filers reported holding DANAHER CORPORATION in Q3 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $85,389 | -13.1% | 387,806 | -5.3% | 0.38% | -8.4% |
| Q2 2023 | $98,316 | -71.9% | 409,650 | -70.5% | 0.42% | -22.3% |
| Q1 2023 | $350,019 | +185.5% | 1,388,754 | +200.7% | 0.53% | -3.6% |
| Q4 2022 | $122,601 | -99.9% | 461,914 | -4.7% | 0.55% | -7.0% |
| Q3 2022 | $125,178,000 | +0.9% | 484,645 | -1.0% | 0.60% | +6.6% |
| Q2 2022 | $124,062,000 | -15.1% | 489,359 | -1.8% | 0.56% | +4.5% |
| Q1 2022 | $146,150,000 | -7.3% | 498,245 | +4.0% | 0.54% | -2.2% |
| Q4 2021 | $157,681,000 | +8.4% | 479,260 | +0.3% | 0.55% | 0.0% |
| Q3 2021 | $145,490,000 | +7.7% | 477,897 | -5.1% | 0.55% | +12.6% |
| Q2 2021 | $135,092,000 | +15.8% | 503,401 | -2.9% | 0.49% | +10.7% |
| Q1 2021 | $116,699,000 | -0.8% | 518,480 | -2.1% | 0.44% | -3.3% |
| Q4 2020 | $117,655,000 | -0.5% | 529,645 | -3.5% | 0.45% | -8.3% |
| Q3 2020 | $118,197,000 | +11.0% | 548,912 | -8.8% | 0.50% | +6.5% |
| Q2 2020 | $106,456,000 | +26.8% | 602,027 | -0.7% | 0.46% | +5.2% |
| Q1 2020 | $83,945,000 | -10.2% | 606,500 | -0.4% | 0.44% | +12.8% |
| Q4 2019 | $93,465,000 | -47.6% | 608,978 | -50.7% | 0.39% | -0.3% |
| Q3 2019 | $178,494,000 | +100.4% | 1,235,864 | +98.3% | 0.39% | -0.8% |
| Q2 2019 | $89,054,000 | +14.6% | 623,110 | +5.8% | 0.40% | +12.5% |
| Q1 2019 | $77,720,000 | +24.8% | 588,706 | -2.5% | 0.35% | +11.4% |
| Q4 2018 | $62,265,000 | -4.8% | 603,816 | +0.3% | 0.32% | +10.1% |
| Q3 2018 | $65,399,000 | +0.7% | 601,870 | -8.6% | 0.29% | +2.5% |
| Q2 2018 | $64,947,000 | -2.2% | 658,163 | -2.9% | 0.28% | -4.8% |
| Q1 2018 | $66,386,000 | -7.3% | 678,033 | -12.1% | 0.29% | -3.9% |
| Q4 2017 | $71,586,000 | -12.6% | 771,238 | -19.3% | 0.31% | -13.1% |
| Q3 2017 | $81,937,000 | -0.9% | 955,209 | -2.5% | 0.35% | -4.3% |
| Q2 2017 | $82,677,000 | -2.9% | 979,713 | -1.6% | 0.37% | -0.3% |
| Q1 2017 | $85,145,000 | +14.7% | 995,505 | +4.4% | 0.37% | +12.8% |
| Q4 2016 | $74,256,000 | +2.0% | 953,959 | +2.7% | 0.33% | +0.6% |
| Q3 2016 | $72,808,000 | -23.4% | 928,799 | -1.3% | 0.32% | -23.2% |
| Q2 2016 | $95,044,000 | -38.2% | 941,031 | -41.9% | 0.42% | -34.2% |
| Q1 2016 | $153,728,000 | +104.4% | 1,620,578 | +100.1% | 0.64% | +91.4% |
| Q4 2015 | $75,220,000 | +7.4% | 809,871 | -1.4% | 0.34% | +0.9% |
| Q3 2015 | $70,018,000 | -1.7% | 821,722 | -1.3% | 0.33% | +6.4% |
| Q2 2015 | $71,241,000 | -2.6% | 832,352 | -3.4% | 0.31% | -3.1% |
| Q1 2015 | $73,154,000 | -1.4% | 861,649 | -0.5% | 0.32% | +0.3% |
| Q4 2014 | $74,204,000 | -44.8% | 865,754 | -51.0% | 0.32% | +0.9% |
| Q3 2014 | $134,350,000 | +79.8% | 1,768,228 | +86.3% | 0.32% | -4.2% |
| Q2 2014 | $74,724,000 | -11.1% | 949,114 | -15.3% | 0.33% | -11.9% |
| Q1 2014 | $84,055,000 | -20.4% | 1,120,728 | -18.0% | 0.38% | -20.4% |
| Q4 2013 | $105,535,000 | -3.2% | 1,367,028 | -13.0% | 0.48% | -1.0% |
| Q3 2013 | $108,968,000 | +2.7% | 1,571,954 | -6.2% | 0.48% | +5.3% |
| Q2 2013 | $106,073,000 | – | 1,675,718 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |